Full-Time

Senior Engineer

Full Stack Software

Posted on 8/14/2025

Strand Therapeutics

Strand Therapeutics

51-200 employees

Develops programmable, long-acting mRNA therapeutics

No salary listed

Boston, MA, USA

In Person

Category
Software Engineering (1)
Requirements
  • B.S. or M.S. in Computer Science, Electrical Engineering, Data Science, Bioengineering, or a related field, and 3+ years of experience.
  • Experience in biology-related fields highly preferred; Experience working in a smaller, fast paced environment highly preferred.
  • Expertise in programming languages, especially Python, and their ecosystems in web development and data analysis; Familiarity with a variety of programming languages and paradigms.
  • Expertise in front-end programming with JavaScript, HTML, and CSS; Experience with front-end frameworks like React or Vue.
  • Expertise in databases and storage technologies; SQL.
  • Comfortable using Unix environments (Linux, shell scripting).
  • Experience with common software tooling, including version control with git and deployment automation with Docker, Ansible, CloudFormation, or similar; Experience with automated testing.
  • Experience with cloud computing (AWS) is a requirement; Experience with high performance or scientific computing is a nice-to-have.
  • Strong collaboration and inter-personal skills.
  • Ability to engage with the diverse stakeholders on any software project is a must.
  • Ability to multi-task and prioritize to meet important deadlines.
Responsibilities
  • Build, validate, deploy, and operate computational tools for analyzing and optimizing mRNA therapeutics in collaboration with other scientists and engineers.
  • Build primarily internal facing tools supporting diverse computational biology and data handling efforts such as large-scale next generation sequencing analysis; clinical data warehousing and pipelines; data capture, storage, and analysis for diverse scientific workflows; and machine learning model training and deployment.
  • Build full stack web applications from database to API to GUI.
  • Build gen-AI applications for workflow streamlining, integrate internal data stores
  • Work with stakeholders across the company to integrate data access and computation through APIs. Integrate 3rd party data sources and tools.
  • Manage the complete software development lifecycle from conception and requirements gathering to implementation, deployment, and operation.
  • Contribute to architecture and implement cloud computational infrastructure.
  • Mentor team members in software development tools, best practices, and problem solving.
  • Engage with cross-functional project teams and external collaborators to support project planning and execution, provide expert advice, and drive adoption of software-based solutions.

Strand Therapeutics develops programmable, long-acting mRNA therapeutics that aim to treat cancer and other life-threatening diseases. The product works by delivering mRNA engineered with logic-based circuits that sense disease-specific cell signals and activate only in diseased cells, increasing the therapeutic window and reducing harm to healthy cells. This enables multi-functional treatments with targeted action rather than non-specific delivery. The company differentiates itself by its programmable mRNA platform that combines gene-encoded logic with disease targeting to achieve cell-type–restricted activity, potentially allowing for safer and more precise therapies compared with conventional mRNA approaches. Strand Therapeutics pursues collaboration and partnerships to expand its programs and generate revenue through development and commercialization of its proprietary mRNA therapeutics with healthcare providers and institutions.

Company Size

51-200

Company Stage

Series B

Total Funding

$256M

Headquarters

Cambridge, Massachusetts

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • STX-001 Phase 1 showed confirmed complete response and partial responses by April 2025.
  • $153M Series B from Regeneron, Lilly, Amgen funds STX-003 Phase 1 in 2026.
  • New CFO Kunal Bhatia and CMO Jason Luke strengthen leadership for Phase 2 transition.

What critics are saying

  • Regeneron's liblocalcin achieves 62% ORR in refractory melanoma, eroding STX-001 edge.
  • FDA clinical hold on self-replicating RNA like Gritstone's halts STX-001 by Q2 2026.
  • Eli Lilly enforces milestone repayment if STX-001 misses 20% ORR in Q4 2026 readout.

What makes Strand Therapeutics unique

  • STX-001 deploys programmable mRNA with logic circuits sensing diseased cells only.
  • Intratumoral STX-001 produces localized IL-12, activating immunity without systemic toxicity.
  • Platform enables cell-type specific, multi-functional mRNA therapies for solid tumors.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Life Insurance

Unlimited Paid Time Off

Phone/Internet Stipend

Commuter Benefits

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-4%
The Pharma Data
Aug 23rd, 2025
Strand Therapeutics Names Dr. Jason J. Luke as New Chief Medical Officer

Strand Therapeutics strengthens leadership with appointment of Dr. Jason J. Luke as Chief Medical Officer.

BiopharmaTrend
Aug 11th, 2025
Strand Therapeutics Secures $153 Million for Programmable mRNA Cancer Therapies

Kinnevik's Ala Alenazi, Ph.D., will join Strand's board of directors.

Crunchbase
Aug 8th, 2025
The Week's 10 Biggest Funding Rounds: Public Safety Leads, While Healthcare And Fintech Also See Big Deals

Strand Therapeutics, $153M, biotechnology: Boston-based Strand Therapeutics, a developer of mRNA-based therapeutics, raised $153 million in a Series B funding led by Kinnevik.

Business Wire
Aug 8th, 2025
Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline

Strand Therapeutics raised a $153 million Series B to develop programmable mRNA therapeutics and reshape how we treat disease -- starting with cancer.

BioSpace
Aug 7th, 2025
Big Pharma-Backed mRNA Startup Bags $153M Series B Amid Policy Headwinds

Strand Therapeutics on Thursday closed a $153 million series B round that will help it advance its pipeline of novel mRNA therapies for cancer and other chronic conditions.

INACTIVE